8.91
price up icon0.79%   0.07
after-market After Hours: 8.90 -0.010 -0.11%
loading
Biomea Fusion Inc stock is traded at $8.91, with a volume of 802.91K. It is up +0.79% in the last 24 hours and down -14.98% over the past month. Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
See More
Previous Close:
$8.84
Open:
$8.9
24h Volume:
802.91K
Relative Volume:
1.07
Market Cap:
$322.89M
Revenue:
-
Net Income/Loss:
$-117.26M
P/E Ratio:
-2.6837
EPS:
-3.32
Net Cash Flow:
$-99.96M
1W Performance:
-26.12%
1M Performance:
-14.98%
6M Performance:
-27.85%
1Y Performance:
-11.69%
1-Day Range:
Value
$8.60
$9.095
1-Week Range:
Value
$8.60
$12.18
52-Week Range:
Value
$3.61
$22.74

Biomea Fusion Inc Stock (BMEA) Company Profile

Name
Name
Biomea Fusion Inc
Name
Phone
(650) 980-9099
Name
Address
900 MIDDLEFIELD ROAD, REDWOOD CITY
Name
Employee
107
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
BMEA's Discussions on Twitter

Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-09-24 Initiated Edward Jones Buy
Sep-27-24 Upgrade Rodman & Renshaw Neutral → Buy
Sep-27-24 Upgrade Truist Hold → Buy
Aug-29-24 Initiated CapitalOne Overweight
Jun-11-24 Downgrade Truist Buy → Hold
Jun-07-24 Downgrade Barclays Overweight → Equal Weight
Apr-02-24 Downgrade JP Morgan Overweight → Neutral
Feb-06-24 Initiated Truist Buy
Jul-27-23 Initiated Scotiabank Sector Outperform
Jun-26-23 Downgrade Jefferies Buy → Hold
May-12-23 Initiated Barclays Overweight
Mar-29-23 Reiterated Oppenheimer Outperform
Mar-28-23 Reiterated H.C. Wainwright Buy
Feb-24-23 Initiated Citigroup Buy
Jun-02-22 Resumed H.C. Wainwright Buy
Jan-12-22 Initiated H.C. Wainwright Buy
Dec-17-21 Initiated Oppenheimer Outperform
May-11-21 Initiated JP Morgan Overweight
May-11-21 Initiated Jefferies Buy
May-11-21 Initiated Piper Sandler Overweight
View All

Biomea Fusion Inc Stock (BMEA) Latest News

pulisher
03:08 AM

Biomea Fusion, Inc. Reveals Preclinical Data on Icovamenib and BMF-650 in Recent SEC Filing - Defense World

03:08 AM
pulisher
Nov 04, 2024

Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook - Investing.com India

Nov 04, 2024
pulisher
Nov 04, 2024

Biomea Fusion FY2024 EPS Estimate Raised by HC Wainwright - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Biomea Fusion (NASDAQ:BMEA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Biomea Fusion’s (BMEA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Nov 04, 2024
pulisher
Nov 02, 2024

BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan

Nov 02, 2024
pulisher
Nov 01, 2024

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Biomea Fusion stock PT raised by Piper Sandler, citing pipeline potential - Investing.com Australia

Nov 01, 2024
pulisher
Oct 31, 2024

HC Wainwright Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Biomea Fusion Unveils Promising Diabetes Treatment Innovations - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Biomea Fusion Reports Q3 2024 Financial Results - MSN

Oct 30, 2024
pulisher
Oct 30, 2024

Biomea Fusion Presents Preclinical Data Showing Icovamenib - GlobeNewswire

Oct 30, 2024
pulisher
Oct 30, 2024

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Barclays Forecasts Strong Price Appreciation for Biomea Fusion (NASDAQ:BMEA) Stock - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Biomea Awaits 2 Data Readouts Of Diabetes StudiesCan The Stock Get Its Mojo Back? - RTTNews

Oct 30, 2024
pulisher
Oct 30, 2024

Biomea Fusion (NASDAQ:BMEA) Announces Earnings Results - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Biomea Fusion price target raised to $11 from $9 at Barclays - TipRanks

Oct 30, 2024
pulisher
Oct 29, 2024

Biomea Fusion reports Q3 EPS (91c), consensus (95c) - TipRanks

Oct 29, 2024
pulisher
Oct 29, 2024

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights - GlobeNewswire

Oct 29, 2024
pulisher
Oct 28, 2024

Biomea Fusion options imply 6.1% move in share price post-earnings - TipRanks

Oct 28, 2024
pulisher
Oct 28, 2024

Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Brokerages - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Oct 28, 2024
pulisher
Oct 27, 2024

(BMEA) Technical Data - Stock Traders Daily

Oct 27, 2024
pulisher
Oct 22, 2024

Biomea Fusion shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Biomea Fusion's (BMEA) Buy Rating Reiterated at HC Wainwright - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Biomea Fusion shares maintain Buy rating from H.C. Wainwright - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Exchange Traded Concepts LLC Acquires 8,079 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World

Oct 22, 2024
pulisher
Oct 21, 2024

Biomea Fusion's icovamenib gets global and US naming approval - Investing.com India

Oct 21, 2024
pulisher
Oct 21, 2024

Biomea Fusion's icovamenib gets global and US naming approval By Investing.com - Investing.com South Africa

Oct 21, 2024
pulisher
Oct 21, 2024

Biomea Fusion announces approval of ‘icovamenib’ as INN for BMF-219 - TipRanks

Oct 21, 2024
pulisher
Oct 21, 2024

Biomea Fusion Announces Approval of 'icovamenib” as International Nonproprietary Name for BMF-219 - The Manila Times

Oct 21, 2024
pulisher
Oct 21, 2024

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219 - GlobeNewswire

Oct 21, 2024
pulisher
Oct 19, 2024

Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World

Oct 19, 2024
pulisher
Oct 16, 2024

(BMEA) Investment Analysis and Advice - Stock Traders Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Griffin Asset Management Inc. Purchases 57,180 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-21 - The Manila Times

Oct 15, 2024
pulisher
Oct 15, 2024

Biomea Fusion to Host Conference Call and Webcast on - GlobeNewswire

Oct 15, 2024
pulisher
Oct 13, 2024

Marshall Wace LLP Sells 3,900 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World

Oct 13, 2024
pulisher
Oct 13, 2024

Squarepoint Ops LLC Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat

Oct 13, 2024
pulisher
Oct 12, 2024

Investigation Launched into Biomea Fusion Securities - Bit Perfect Solutions

Oct 12, 2024
pulisher
Oct 10, 2024

Biomea Fusion (NASDAQ:BMEA) Upgraded at EF Hutton Acquisition Co. I - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Biomea Fusion shares recieve Buy rating from EF Hutton - Investing.com

Oct 09, 2024
pulisher
Oct 09, 2024

Biomea Fusion shares recieve Buy rating from EF Hutton By Investing.com - Investing.com UK

Oct 09, 2024
pulisher
Oct 09, 2024

Biomea Fusion initiated with a Buy at EF Hutton - TipRanks

Oct 09, 2024
pulisher
Oct 07, 2024

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) - The Manila Times

Oct 07, 2024
pulisher
Oct 07, 2024

Biomea Fusion to Present at the 1st Annual Asian Conference - GlobeNewswire

Oct 07, 2024
pulisher
Oct 07, 2024

Point72 Asia Singapore Pte. Ltd. Acquires New Stake in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World

Oct 07, 2024
pulisher
Oct 05, 2024

Renaissance Technologies LLC Purchases Shares of 329,106 Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World

Oct 05, 2024
pulisher
Oct 05, 2024

Renaissance Technologies LLC Purchases New Shares in Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat

Oct 05, 2024

Biomea Fusion Inc Stock (BMEA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):